Global News

Lycera names Paul Sekhri president and CEO

Thursday, February 5, 2015 12:58 PM

Lycera, a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease, has named Paul Sekhri president, CEO and a member of the board of directors, effective immediately. Sekhri brings more than 25 years of operational experience in the life sciences industry, including business development and strategy, general management, drug development, and commercial strategy.  He succeeds Kathleen M. Metters, Ph.D., who currently serves as senior advisor to the company.

More... »


NIHR, Janssen partner on rheumatoid arthritis biological treatments

Thursday, February 5, 2015 12:50 PM

A new clinical research study has been launched that will explore why the current gold standard biological treatment for people with rheumatoid arthritis does not work in around a third of patients. The National Institute for Health Research (NIHR) study in partnership with Janssen will investigate key mechanisms associated with a lack of response to this treatment and its findings should open new routes for developing therapies for these patients.

More... »


Neomed creates a new Biologics and Vaccine Center of Excellence

Thursday, February 5, 2015 12:15 PM

Neomed has launched the Biologics and Vaccine Center of Excellence in Laval under a proposed partnership with GlaxoSmithKline (GSK). This Center will be unique in Canada and GSK has committed $47 million towards its establishment. Neomed is a nonprofit that fosters the development of promising therapeutic approaches emerging from academia and biotechnology companies and is jointly funded by the pharmaceutical industry, the Ministère de l'Économie, de l'Innovation et des Exportations du Québec and the Networks of Centers of Excellence (NCE) of Canada.

More... »

The Medicines Company acquires Annovation Biopharma

Thursday, February 5, 2015 12:08 PM

The Medicines Company has completed its acquisition of all of the outstanding equity of Annovation Biopharma, a company focused on creating more effective, safer therapies for anesthesia and critical care. Based on technology licensed from Massachusetts General Hospital, Annovation is developing ABP-700, a novel intravenous anesthetic which in phase I clinical studies has demonstrated potent and rapidly reversible anesthetic effects.

More... »

Pfizer to acquire Hospira for $17 billion

Thursday, February 5, 2015 12:06 PM

Pfizer has agreed to acquire Hospira, a provider of injectable drugs and infusion technologies and a global provider in biosimilars headquartered in Lake Forest, Ill., for $90 a share in cash, for a total enterprise value of approximately $17 billion.

More... »

Theravance Biopharma, Mylan partner for COPD

Wednesday, February 4, 2015 01:43 PM

Theravance Biopharma, based in south San Francisco, Calif., and Mylan, a global generic and specialty pharmaceuticals company headquartered in Cecil Township, Pa., will partner on the development and commercialization of TD-4208, a novel investigational once-daily nebulized long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease (COPD) and other respiratory diseases.

More... »

COMBACTE-MAGNET launched to revitalize antibiotic development

Wednesday, February 4, 2015 01:41 PM

Thirty-three European academic partners and five pharmaceutical companies are launching a new project, COMBACTE-MAGNET, under the Innovative Medicines Initiative (IMI) antimicrobial resistance research program New Drugs 4 Bad Bugs (ND4BB).

More... »

Water Street invests in generic injectable drug services company Custopharm

Wednesday, February 4, 2015 01:32 PM

Water Street Healthcare Partners, a strategic investor focused exclusively on the healthcare industry headquartered in Chicago, has invested in Custopharm, a generic injectable drug services company. Water Street's team has committed equity to both acquire and expand the Carlsbad, Calif.-based company. The healthcare firm has recruited William Larkins, Ph.D., former vice president and general manager of Bedford Laboratories, as CEO of Custopharm.

More... »

Accelerated Cure Project for Multiple Sclerosis has launched iConquerMS

Wednesday, February 4, 2015 01:26 PM

The Accelerated Cure Project for Multiple Sclerosis has launched iConquerMS, a nationwide initiative by and for individuals living with multiple sclerosis who recognize the power of their health data and insights and want to harness that power to fuel research. The initiative's portal, www.iConquerMS.org, enables all people living with MS to play an active role in research, empowering them to securely submit their health data, propose topics of research that are most important to them, influence the research that is carried out by the initiative and become informed about the research process and specific studies.

More... »

CSSi LifeSciences introduces SmartStudy Design and Feasibility

Wednesday, February 4, 2015 01:25 PM

CSSi LifeSciences, a Glen Burnie, Md.-based provider of fully integrated solutions that span the lifecycle of a new drug or device, has launched its newest product offering in its portfolio of services—SmartStudy Design and Feasibility. CSSi LifeSciences is a partner company of global patient recruitment solutions provider CSSi.

More... »

`

CWWeekly

February 23

Venture capital investors funding novel drug R&D three times more than companies repurposing, improving existing drugs

In appreciation: Karen Woodin will be remembered for her teaching, writing and lasting friendships

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs